Masks

Drug Treatment

Clinical Factors

Testing

Miscellaneous

Masks in healthcare workers; -Surgical masks and respirators (N95) appear similar in preventing viral infections, [N95 masks having slightly – not statistically different- lower infection rates (~1-2%). -Cloth masks are poorer than surgical (with ~2% RTI x4 wks). -No RCTs examined transmission to others or COVID-19. -Masks just one-part PPE and transmission precautions. Without further evidence, <u>hydroxychloroquine</u> is not appropriate for patients with COVID-19 in primary care. A number of recent trials/studies show an increased risk of side effects and QT prolongation especially at higher doses. RCTs are ongoing and hopefully they will provide more insight into the benefit/harm of this empiric treatment. Cough, fever and dyspnea are the most common <u>symptoms</u> of COVID-19.
At least 80% of cases are clinically mild, ~10% are hospitalized and 25% of admitted patients require intensive care.
Mortality risk factors include long-term care residents, age >65, co-morbid illnesses, and COVID-19 associated cardiac

injury.

Alberta College of
 Family Physicians

Studies of clinical <u>PCR</u> <u>sensitivity</u> are limited and vary widely for many reasons. Even if test sensitivity ranged between 50-90%, patients with low pretest probability (example 10%) would have at worst a 5% false negative rate. There is no reliable evidence that <u>NSAIDs, ACE inhibitors</u> <u>or ARBs</u> increase the risk of COVID-19 or affect disease severity/mortality from COVID-19

Mask in the community may reduce transmission of viral RTI (from 2 RCTs). If community risk was ~25% over 6 weeks, masks could decrease that to ~19%. No COVID-19 research, many studies examined others risk once someone was sick, and the overall certainty of evidence is low. Any mask use should be combined with social distancing and other preventive strategies

PEER PATIENTS EXPERIENCE EVIDENCE RESEARCH To date, no published RCTs have demonstrated benefit of treating COVID-19 patients with <u>remdesivir, lopinavir–ritonavir or</u> <u>oseltamivir</u>. One interim analysis of remdesivir suggests improved time to recovery. Full publication of studies and ongoing trials will help to answer this question. <u>Transmission</u> of COVID-19 can occur in people who are currently asymptomatic (including those who will remain asymptomatic and those who are early and not symptomatic yet). Case reports suggest this occurs in 6-13% of cases, although modelling suggests this might be higher. ~50% of carriers are asymptomatic when an entire population is tested. While IGM and IGG antibodies (<u>serology</u>) may tell and individuals recent or past exposure – it is unclear whether antibodies confer immunity to subsequent infection. Accuracy of antibody testing likely requires validation in large number of infected and noninfected individuals.

Tools for Practice Unfortunately, no specific technique, including the Roth Score, reliably assures dyspneic patients are safe. No studies assessed <u>dyspnea</u> in COVID-19 patients. Clinicians are encouraged to use available tools (BMJ Virtual Assessment tool) and have patients assessed inperson if any concerns.



THE COLLEGE OF FAMILY PHYSICIANS OF CANADA

